External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

HealthCare Global Enterprises / Equity Bottom-Up

HealthCare Global Enterprises Limited provides medical and surgical hospital services. The Hospital offers cancer care, chemotherapy, cyberknife surgery, surgical, radiation, and medical oncology services. HealthCare Global Enterprises operates worldwide.

<ul><li>HCG’s management hosted an investor and analyst interaction where the new CEO, Mr. Manish Mattoo (a practicing anaesthesiologist and MBA in Finance), outlined a clear four-pillar strategy centered on clinical outcomes, profitable growth, capital efficiency, and patient experience.</li><li>There will be a shift in the reporting framework from the “mature vs. new” category to regional clusters and oncology-appropriate KPIs such as ARPP and patient volumes.</li><li>The medium-term aspiration is to grow ahead of the industry, improve EBITDA margins beyond the historical CAGR, and uplift company-level ROCE to 20% as more centres mature.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HCG’s management hosted an investor and analyst interaction where the new CEO, Mr. Manish Mattoo (a practicing anaesthesiologist and MBA in Finance), outlined a clear four-pillar strategy centered on clinical outcomes, profitable growth, capital efficiency, and patient experience.There will be a shift in the reporting framework from the “mature vs. new” category to regional clusters and oncology-appropriate KPIs such as ARPP and patient volumes.The medium-term aspiration is to grow ahead of the industry, improve EBITDA margins beyond the historical CAGR, and uplift company-level ROCE to 20% as more centres mature.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare Global Enterprises Ltd - 5 Th December, 2025

Global Healthcare Analyst

Tina Banerjee

Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kyowa-kirin-co-ltd" target="_blank" data-smartkarma-citation="entities:18055:1" rel="noopener">Kyowa Kirin Co Ltd (4151 JP) </a>announced that ziftomenib is now commercially available in the U.S. Company will be eligible for 50% profit sharing from drug sales in the U.S.</li>
<li>Rocatinlimab, under Phase 3 trials, represents a potentially novel upstream approach for the management of mild to severe atopic dermatitis. It is also undergoing Phase 3 trials for Prurigo nodularis.</li>
<li>2026 will be an inflection point. Ziftomenib results will slowly fall in place. Positive results of rocatinlimab and new manufacturing facilities has potential to play out in long term.</li>
</ul>



Kyowa Kirin Co Ltd (4151 JP) announced that ziftomenib is now commercially available in the U.S. Company will be eligible for 50% profit sharing from drug sales in the U.S.
Rocatinlimab, under Phase 3 trials, represents a potentially novel upstream approach for the management of mild to severe atopic dermatitis. It is also undergoing Phase 3 trials for Prurigo nodularis.
2026 will be an inflection point. Ziftomenib results will slowly fall in place. Positive results of rocatinlimab and new manufacturing facilities has potential to play out in long term.


Kyowa Kirin (4151 JP): Ziftomenib Approval and Commercialization A Positive, What Lies Ahead?

Director, RaaS Research Group, Research as a Service (RaaS)

RaaS Research Group (RaaS)

Director, RaaS Research Group

Insightful Financial Models and Research Analysis

Research as a Service (RaaS)

Connect to the right investors through smart and insightful financial models and research analysis.

Cleanspace Holdings Ltd / Equity Bottom-Up

Cleanspace Holdings Limited designs and manufactures medical equipment. The Company offers respiratory protective masks and air purifying respirators that provide respiratory protection. Cleanspace serves customers worldwide.

<ul><li>CleanSpace Holdings Ltd (ASX:CSX) is a designer and manufacturer of respiratory protection equipment and consumables for powered air purifying respirators (PAPRs).</li><li>CSX has provided a trading update at their AGM which guides to lower H1 FY26 revenue growth relative to previous halves and RaaS estimates (+27%), impacted by trade and tariff tensions not dis-similar to trends seen for several advanced Australian manufacturers including Veem (ASX:VEE) and Austin Engineering (ASX:ANG), and the dismantling of key US safety regulator NIOSH.</li><li>Gross margins remain in-line with estimates around the ‘mid-70s’ and costs are well controlled.</li></ul>

CleanSpace Holdings Ltd (ASX:CSX) is a designer and manufacturer of respiratory protection equipment and consumables for powered air purifying respirators (PAPRs).CSX has provided a trading update at their AGM which guides to lower H1 FY26 revenue growth relative to previous halves and RaaS estimates (+27%), impacted by trade and tariff tensions not dis-similar to trends seen for several advanced Australian manufacturers including Veem (ASX:VEE) and Austin Engineering (ASX:ANG), and the dismantling of key US safety regulator NIOSH.Gross margins remain in-line with estimates around the ‘mid-70s’ and costs are well controlled.

Cleanspace Holdings Ltd - Several headwinds slow growth in H1

Japan Experts, Extraordinary Performance, Astris Advisory Japan

Astris Advisory Japan

Japan Experts, Extraordinary Performance

Our Corporate Advisory service is designed to give clients access to a wider range of investors. These include Japan specialists as well as global investors. The goal is to help achieve a fair equity valuation.

JTEC Corporation of Osaka manufactures bio-technology systems and equipment. The Company produces life science devices, x ray mirrors, and automated cell culture systems. JTEC also develops pharmaceutical products. JTEC serves clients in Japan.

<ul><li>A soft start – Q1 FY6/26 results were relatively soft, with sales flat and OP still in negative territory.</li><li>This reflects the seasonally weak nature of Q1 and continued spending on R&amp;D.</li><li>The Optical segment remained strong, supported by resilient global demand, while the Life Science &amp; Equipment Development segment continued to progress, driven by consumables, maintenance services, and semiconductor equipment currently in the testing stage. </li></ul>

A soft start – Q1 FY6/26 results were relatively soft, with sales flat and OP still in negative territory.This reflects the seasonally weak nature of Q1 and continued spending on R&amp;D.The Optical segment remained strong, supported by resilient global demand, while the Life Science &amp; Equipment Development segment continued to progress, driven by consumables, maintenance services, and semiconductor equipment currently in the testing stage. 

JTEC Corp (3446 JP) - Strength in Optical Remains, Progress in Semiconductor

Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

SYSMEX CORPORATION manufactures reagents and equipment for clinical tests including hematologic (blood) and immune tests. The Company also develops, manufactures, and trades particle analyzers such as blood coagulation analyzer and related software. Manufacturing and sales outside Japan include the United States, EMEA, China and Asia Pacific regions.

<ul>
 <li>
<a href="https://smartkarma.com/entities/sysmex-corp-ffe73c3c-d212-47dd-bab3-0464ba1958fe">Sysmex </a>is a global leader in the in-vitro diagnostics (IVD) market, with a dominant position in the hematology segment and a strong presence in urinalysis and hemostasis. The company's business model is driven by the sale of diagnostic instruments and the recurring revenue from high-margin reagents.</li>
 <li>Growth is supported by favorable long-term trends, including aging populations, rising prevalence of chronic diseases, and increasing healthcare access in emerging markets. <a href="https://smartkarma.com/entities/sysmex-corp-ffe73c3c-d212-47dd-bab3-0464ba1958fe">Sysmex </a>is strategically focused on expanding its footprint in these high-growth regions, particularly in Asia.</li>
 <li>While the company has a strong track record of revenue growth and profitability, it faces challenges from intensifying competition, pricing pressure from healthcare cost-containment measures, and the need for continuous innovation to maintain its technological edge.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Sysmex is a global leader in the in-vitro diagnostics (IVD) market, with a dominant position in the hematology segment and a strong presence in urinalysis and hemostasis. The company's business model is driven by the sale of diagnostic instruments and the recurring revenue from high-margin reagents.
  Growth is supported by favorable long-term trends, including aging populations, rising prevalence of chronic diseases, and increasing healthcare access in emerging markets. Sysmex is strategically focused on expanding its footprint in these high-growth regions, particularly in Asia.
  While the company has a strong track record of revenue growth and profitability, it faces challenges from intensifying competition, pricing pressure from healthcare cost-containment measures, and the need for continuous innovation to maintain its technological edge.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.